4DMedical Secures Commercial SimonMed Contract Across 170 US Imaging Centres
4DMedical (ASX: 4DX) has secured a landmark three-year commercial agreement with SimonMed Imaging to deploy CT:VQ™ and LDAf™ across more than 170 US outpatient imaging centres, marking a pivotal shift from academic validation to scaled commercial revenue generation.
Key Takeaways
- 4DMedical has signed a three-year commercial agreement with SimonMed Imaging covering more than 170 outpatient imaging centres across 10 US states, supported by over 300 radiologists.
- The agreement goes directly to commercial deployment on a per-scan SaaS pricing basis with no evaluation or pilot phase, signalling strong conviction from one of the US's largest outpatient imaging networks.
- SimonMed will share insurance and claims data across its network to support 4DMedical's reimbursement evidence development, a critical step toward securing Medicare and commercial insurer coverage.
- The partnership validates 4DMedical's dual-track strategy of leveraging academic medical centres for clinical credibility while pursuing high-volume outpatient networks for scalable recurring revenue.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.